- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00968890
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix™ 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study will be conducted in an open manner regarding the administration of vaccine GSK2340272A.
The study will be observer-blind regarding the administration of Fluarix™ and placebo vaccines.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Eskilstuna, Szwecja, SE-631 88
- GSK Investigational Site
-
Örebro, Szwecja, SE-703 62
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female subjects 61 years of age or older at the time of the first vaccination
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject.
- Satisfactory baseline medical assessment by history and physical examination.
- Access to a consistent means of telephone contact.
Exclusion Criteria:
- Previous administration of the 2009 Southern Hemisphere or 2009-2010 Northern Hemisphere seasonal influenza vaccine.
- Previous administration of a pandemic influenza vaccine.
- Administration of any vaccine within 30 days before first vaccination.
- Planned administration of a vaccine not foreseen by the study protocol one month (minimum 30 days) after the second vaccination with vaccine GSK2340272A.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of the study vaccines or planned use during the study period. Potential subjects in the follow-up (i.e., no treatment) phase of a prior investigational study may be enrolled if the investigator's judgment is that it will have no effect on safety, reactogenicity, or immunogenicity endpoints in this study, and that it does not violate the protocol requirements of the prior trial.
- Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- Presence of an oral temperature >= 37.5°C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
- Diagnosed with cancer, or treatment for cancer, within 3 years.
- Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
- Chronic administration of immunosuppressants or other immune modifying drugs within six months prior to the first vaccination.
- Receipt of any immunoglobulins and/or any blood products within 3 months preceding the first vaccination or planned administration of any of these products during the entire study period.
- Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic anti-platelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.
- An acute evolving neurological disorder or history of Guillain-Barré syndrome.
- Serious chronic disease as determined by medical history and physical examination.
- Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormalities, as determined by physical examination or laboratory screening tests.
- Any known or suspected allergy to any constituent of influenza vaccines.
- History of chronic alcohol consumption and/or drug abuse.
- Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
- Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Pandemrix+Fluarix and Pandemrix+Placebo
Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
|
Intramuscular injection, 2 doses
Intramuscular injection, 1 dose
Inne nazwy:
Intramuscular injection, 1 dose
|
Eksperymentalny: Pandemrix+Placebo and Pandemrix+Fluarix
Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
|
Intramuscular injection, 2 doses
Intramuscular injection, 1 dose
Inne nazwy:
Intramuscular injection, 1 dose
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Seroconverted Subjects After the Second Dose of Pandemrix and After Vaccination With Fluarix
Ramy czasowe: 21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
A seroconverted subject is a subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer < 10 and a postvaccination reciprocal titer >= 40, or a pre-vaccination reciprocal HI titer >= 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
Number of Seroprotected Subjects After the Second Dose of Pandemrix and After Vaccination With Fluarix
Ramy czasowe: 21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
A seroprotected subject was a subject with reciprocal HI titers >= 40 against the vaccine homologous virus. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
Geometric Mean Fold Rise (GMFR) After the Second Dose of Pandemrix and After Vaccination With Fluarix
Ramy czasowe: 21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
The GMFR is defined as the Geometric Mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
21 days after the second dose of Pandemrix (=Day 42) and after vaccination with Fluarix (=Day 21 for Pandemrix+Fluarix and Pandemrix+Placebo Group or Day 42 for Pandemrix+ Placebo and Pandemrix+Fluarix Group)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Geometric Mean Titers for Antibodies Against Pandemrix and Fluarix Vaccine Strains
Ramy czasowe: Days 0, 21, 42, 182, 364
|
Titers are expressed as GMTs. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
Days 0, 21, 42, 182, 364
|
Number of Seroconverted Subjects
Ramy czasowe: at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
A seroconverted subject is a subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer < 10 and a postvaccination reciprocal titer >= 40, or a pre-vaccination reciprocal HI titer >= 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
Number of Seroprotected Subjects
Ramy czasowe: at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
A seroprotected subject is a subject with reciprocal HI titers >= 40 against the vaccine homologous virus.
The Pandemrix vaccine strain was A/Cal/09.
The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08.
|
at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
Geometric Mean Fold Rise (GMFR)
Ramy czasowe: at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
The GMFR is defined as the Geometric Mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.
The Pandemrix vaccine strain was A/Cal/09.
The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08.
|
at Day 21 (for Pandemrix vaccine strain only), Day 182 and Day 364
|
Number of Subjects With Titers Equal to or Above Titer 1:10
Ramy czasowe: Days 0, 21, 42, 182, 364
|
The cut-off 1:10 was considered as seropositivity. The Pandemrix vaccine strain was A/Cal/09. The Fluarix vaccine strains were A/Bri/07, A/Uru/07 and B/Bri/08. |
Days 0, 21, 42, 182, 364
|
Number of Subjects With Solicited Local and General Symptoms
Ramy czasowe: Within 7 days (Day 0-Day 6) after each vaccination
|
Solicited local symptoms are pain, redness and swelling at the injection site.
They are divided between solicited local symptoms occurring after administration of Pandemrix, Fluarix or Placebo.
Solicited general symptoms are fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (defined as axillary temperature >= 38.0 degrees Celsius).
|
Within 7 days (Day 0-Day 6) after each vaccination
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Ramy czasowe: From Day 0 to Day 83
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms
|
From Day 0 to Day 83
|
Number of Subjects With Adverse Events of Specific Interest
Ramy czasowe: From Day 0 to Day 364
|
Adverse events of specific interest include autoimmune diseases and other immune mediated inflammatory disorders.
|
From Day 0 to Day 364
|
Number of Subjects With Serious Adverse Events (SAEs)
Ramy czasowe: From Day 0 to Day 364
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
From Day 0 to Day 364
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 113525
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Badanie danych/dokumentów
-
Formularz zgłoszenia przypadku z adnotacjami
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Specyfikacja zestawu danych
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Indywidualny zestaw danych uczestnika
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan analizy statystycznej
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz świadomej zgody
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Protokół badania
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Raport z badania klinicznego
Identyfikator informacji: 113525Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Grypa
-
Mitsubishi Tanabe Pharma CorporationZakończony
-
Mexican Emerging Infectious Diseases Clinical Research...National Institute of Allergy and Infectious Diseases (NIAID); Coordinación...ZakończonyOstre infekcje dróg oddechowych | Influenza Nos lub choroba grypopodobnaMeksyk
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Zakończony
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDZakończonyGrupa A, C Polisacharydowe zapalenie opon mózgowych | Haemophilus influenza typu bChiny
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; Oct... i inni współpracownicyZakończonyInfekcje pneumokokowe | Zapalenie płuc, bakteryjne | Zapalenie opon mózgowych, bakteryjne | Zapalenie ucha środkowego | Przewlekła infekcja zatok | Infekcja paciorkowcowa | Niedobór przeciwciał | Niedobór dopełniacza | Zakażenia Neisseria | Haemophilus InfluenzaFrancja
-
QIAGEN Gaithersburg, IncZakończonyZakażenia syncytialnym wirusem oddechowym | Grypa A | Rinowirus | Grypa B | Panel zaawansowany QIAGEN ResPlex II | Zakażenie wywołane ludzkim wirusem paragrypy 1 | Paragrypa typu 2 | Paragrypa typu 3 | Paragrypa typu 4 | Ludzki metapneumowirus A/B | Wirus Coxsackie/echowirus | Adenowirusy typu B/C/E | Podtypy koronawirusa... i inne warunkiStany Zjednoczone
Badania kliniczne na Pandemrix (Influenza vaccine GSK2340272A)
-
GlaxoSmithKlineZakończony